Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are Long Term Care Rebates Dangerous?

This article was originally published in RPM Report

Executive Summary

One CMS official thinks it is time for a new business model in long term care. Eliminating rebates to long-term care providers may be necessary to protect patients and Part D plans.

You may also be interested in...

Reinventing Pharmacy: The Bidding for Caremark is Just the Beginning

The battle between CVS and Express Scripts for ownership of Caremark has made little impact on drug-company executives. But there is an important implication for pricing in the Medicare Part D world: CVS wants to use Caremark to help it get higher payments for providing pharmacy services. But in the zero-sum game of reimbursement, any additional profits for chains will likely come from reduced prices on drugs.

Too Many Middlemen? Long-Term Care Pharmacies are Losing Fight for Control of Part D Formularies

Omnicare's lawsuit against UnitedHealth Group is part of a battle for survival by long-term care pharmacy providers. The stakes for manufacturers are high: who can really deliver market share under Part D?

Clear Messages From Part D: Managed Care Learns to Work With Retail Pharmacists

Medicare drug plans and retail pharmacy groups are working together to clean up the mess that plagued the launch of Part D. The manufacturers should pay attention: the result may be new force in drug selection and adherence.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts